← ANALYST RATINGS · TIPRANKS
IQVIA Holdings (IQV): analyst forecast and price target
Analyst consensus
Strong Buy10 Buy1 Hold0 Sell
Ratings of 11 analysts in the last 3 months · top analysts only12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $300, the highest $345, the lowest $270. The average is +12.3% from the last price of $267.
Analyst ratings 20
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $285 → $295+3.5% | Buy | +10.5% | Reiterated | 16.10.26on TipRanks Oct 17 08:14 | −0.4% | ↗ |
| Elizabeth Anderson CFA★★★★★★★★★★#2664 · hits 55% · avg +4.4% | Evercore ISI | $275 → $290+5.5% | Buy | +8.7% | Reiterated | 14.10.26on TipRanks 09:55 | +1.6%next day +3.2% | ↗ |
| Shlomo Rosenbaum★★★★★★★★★★#2540 · hits 54% · avg +4.7% | Stifel Nicolaus | $276 → $303+9.8% | Buy | +13.5% | Reiterated | 14.10.26on TipRanks 06:45 | +1.6%next day +3.2% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $280 → $305+8.9% | Buy | +14.3% | Reiterated | 09.10.26on TipRanks 08:10 | −0.2%next day +1.0% · 5 days +4.7% | ↗ |
| Ann Hynes★★★★★★★★★★#1003 · hits 59% · avg +8.1% | Mizuho Securities | $275 → $300+9.1% | Buy | +12.4% | Reiterated | 07.10.26on TipRanks 07:26 | −0.5%next day +0.7% · 5 days +2.5% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $275 → $300+9.1% | Buy | +12.4% | Reiterated | 07.10.26on TipRanks 03:55 | −0.5%next day +0.7% · 5 days +2.5% | ↗ |
| Ryan Halsted★★★★★★★★★★#3317 · hits 60% · avg +9.0% | RBC Capital | $319 | Buy | +19.5% | Reiterated | 06.10.26on TipRanks 21:45 | −0.5%next day +0.7% · 5 days +2.5% | ↗ |
| Kevin Caliendo★★★★★★★★★★#2646 · hits 56% · avg +5.6% | UBS | $345 | Buy | +29.3% | Initiated | 30.09.26on TipRanks 05:35 | +0.2%next day −3.2% · 5 days −5.9% | ↗ |
| Jailendra Singh★★★★★★★★★★#12131 · hits 43% · avg −6.4% | Truist Financial | $300 → $329+9.7% | Buy | +23.3% | Reiterated | 28.09.26on TipRanks 07:30 | +1.0%next day −0.5% · 5 days −3.0% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $240 → $270+12.5% | Hold | +1.2% | Assigned | 17.09.26on TipRanks 07:50 | −0.9%next day −1.2% · 5 days +1.2% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $282 → $293+3.9% | Buy | +9.8% | Reiterated | 10.09.26on TipRanks 07:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $277 → $287+3.6% | Buy | +7.5% | Reiterated | 10.09.26on TipRanks 07:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $272 → $289+6.2% | Buy | +8.3% | Reiterated | 10.09.26on TipRanks 07:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $256 → $280+9.4% | Hold | +4.9% | Reiterated | 10.09.26on TipRanks 07:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $282 → $293+3.9% | Buy | +9.8% | Reiterated | 10.09.26on TipRanks 07:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $281 → $294+4.6% | Buy | +10.2% | Reiterated | 10.09.26on TipRanks 07:05 | — | |
| Unknown Analyst | Jefferies | $220 → $290+31.8% | Buy | +8.7% | Reiterated | 29.07.26on TipRanks 08:50 | +3.4%next day −5.6% · 5 days −10.2% | ↗ |
| Sean Dodge★★★★★★★★★★#11980 · hits 43% · avg −4.3% | BMO Capital | $210 → $270+28.6% | Buy | +1.2% | Reiterated | 29.07.26on TipRanks 08:18 | +3.4%next day −5.6% · 5 days −10.2% | ↗ |
| Eric Coldwell★★★★★★★★★★#1091 · hits 59% · avg +7.7% | Robert W. Baird | $252 → $287+13.9% | Buy | +7.5% | Reiterated | 29.07.26on TipRanks 06:51 | +3.4%next day −5.6% · 5 days −10.2% | ↗ |
| Charles Rhyee★★★★★★★★★★#1937 · hits 54% · avg +5.6% | TD Cowen | $233 → $288+23.6% | Buy | +7.9% | Assigned | 29.07.26on TipRanks Jul 28 20:30 | +3.4%next day −5.6% · 5 days −10.2% | ↗ |
| Jared Haase★★★★★★★★★★#1700 · hits 89% · avg +24.8% | William Blair | — | Buy | — | Reiterated | 28.07.26on TipRanks 10:20 | +13.7%next day +3.4% · 5 days −10.2% | ↗ |
| Sidharth Sahoo★★★★★★★★★★#9090 · hits 43% · avg −0.9% | HSBC | $210 → $240+14.3% | Buy | −10.1% | Reiterated | 06.07.26on TipRanks 10:30 | −1.4%next day +1.6% · 5 days +1.0% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | — | Buy | — | Reiterated | 29.05.26on TipRanks Jun 1 09:35 | +0.4%next day +2.3% · 5 days +3.2% | ↗ |
| Patrick B Donnelly★★★★★★★★★★#2106 · hits 54% · avg +6.0% | Citi | $200 | Hold | −25.1% | Assigned | 07.04.26on TipRanks 06:35 | −0.1%next day −1.4% · 5 days −2.6% | ↗ |
| David Larsen★★★★★★★★★★#12072 · hits 35% · avg −4.7% | BTIG | — | Hold | — | Reiterated | 05.02.26on TipRanks Feb 6 05:45 | −9.4%next day +1.7% · 5 days −7.2% | ↗ |
| Michael Cherny★★★★★★★★★★#2074 · hits 57% · avg +5.7% | Leerink Partners | $232 → $256+10.3% | Buy | −4.1% | Reiterated | 14.12.25on TipRanks Jan 1 03:00 | +0.8%next day −0.6% · 5 days −0.6% | |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering IQVIA Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $287 at a price of $269 (+6.7%); now: $299 at $267 (+12.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 14 | 10 | 20 | 14 | 15 | 9 |
| Hold | 1 | 2 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 27.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $3.25 (from $3.15 to $3.29). Last quarter: $3.15.
Sales
Next quarter’s sales estimate — $4.4B (from $4.3B to $4.4B). Last quarter: $4.4B.
Best top-analyst consensus in the sector · Healthcare
About IQVIA Holdings
- CEO: Ari Bousbib
- Employees: 94,000
- 2400 Ellis Road, Durham, NC, 27703, US
- www.iqvia.com
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in
Data from the stock’s TipRanks forecast page, read 3 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗